New peer-reviewed, scientific study shows Vyleesi enhances sexual brain processing in premenopausal women with HSDD. Click here to learn more ›

August 2022

Palatin Announces Intent to Effect Reverse Stock Split

Press Releases / By

 Aug 19, 2022, 07:30 ET  Common Stock Will Begin Trading on a Split-Adjusted Basis on August 31, 2022 CRANBURY, N.J., Aug. 19, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that …

Palatin Announces Intent to Effect Reverse Stock Split Read More »

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

Press Releases / By

 Aug 16, 2022, 07:30 ET  Independent Data Monitoring Committee Recommends Continuing Study with Sample Size Target of up to 350 Patients – up to Additional 230 Patients to be Enrolled No Safety Concerns Identified Topline Results Currently Expected Second Quarter Calendar 2023 CRANBURY, N.J., Aug. 16, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), …

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Read More »

Scroll to Top